Last reviewed · How we verify
optimal therapy for cardiaca failure
This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine.
This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine. Used for Atrial fibrillation for stroke prevention, Heart failure with reduced ejection fraction.
At a glance
| Generic name | optimal therapy for cardiaca failure |
|---|---|
| Sponsor | Ministry of Health, Brazil |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, the drug decreases glucose levels in the blood, which can help to reduce blood pressure and improve cardiovascular outcomes in patients with heart failure. This mechanism is thought to be beneficial in reducing the risk of hospitalization and mortality in patients with heart failure.
Approved indications
- Atrial fibrillation for stroke prevention
- Heart failure with reduced ejection fraction
Common side effects
- Increased risk of amputations
- Increased risk of diabetic ketoacidosis
- Hypotension
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- optimal therapy for cardiaca failure CI brief — competitive landscape report
- optimal therapy for cardiaca failure updates RSS · CI watch RSS
- Ministry of Health, Brazil portfolio CI